Successful therapy with rituximab of refractory acute humoral renal transplant rejection: A case report
TRANSPLANTATION PROCEEDINGS, cilt.40, sa.1, ss.302-304, 2008 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 40 Sayı: 1
- Basım Tarihi: 2008
- Doi Numarası: 10.1016/j.transproceed.2007.11.011
- Dergi Adı: TRANSPLANTATION PROCEEDINGS
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.302-304
- Dokuz Eylül Üniversitesi Adresli: Evet
Özet
Acute humoral rejection (AHR) is generally less responsive to conventional anti-rejection treatment with consequent allograft losses. Therapeutic options include antilymphocyte antibody (ATG), intravenous immunglobulin (IVIG), plasmapheresis, or immunoadsorption with protein A together with intensification of immunsuppression with a tacrolimus/mycophenolate mofetil combination. This report describes a transplant recipient who responded to rituximab therapy as treatment for steroid-, ATG-, IVIG-, and plasmapheresis-resistant AHR.